The effect of 17β-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus

Vascular Pharmacology

Volumn 39, Issue 3, 2002, Pages 141-147

  Brussaard, Hanny E ^a,b   Gevers Leuven, Jan A ^b   Krans, H Michiel J ^a   Kluft, Cornelis ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Coagulation; CRP; Fibrinolysis; NIDDM; Oestrogens; Postmenopausal

Indexed keywords

BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; ESTRADIOL; FIBRIN; FIBRINOGEN DEGRADATION PRODUCT; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM INJURY; ESTROGEN THERAPY; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; MEDICAL ASSESSMENT; MENOPAUSAL SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SPOTTING;

BLOOD COAGULATION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; FIBRINOLYSIS; HUMANS; POSTMENOPAUSE; STATISTICS, NONPARAMETRIC;

EID: 0344522712     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(02)00303-8     Document Type: Conference Paper

References (57)

1. Andreotti F., Davies G.J., Hackett D., Khan M.I., de Bart A., Dooijewaard G., Maseri A., Kluft C. Circadian variation of fibrinolytic factors in normal human plasma. Fibrinolysis. 2(Suppl. 2):1988;90-92.
2. Brezinka V., Padmos I. Coronary heart disease risk factors in women. Eur. Heart J. 15:1994;1571-1584.
3. Brussaard H.E., Gevers Leuven J.A., Krans H.M.J., Meijer P., Buytenhek R., Kluft C. Non-esterified fatty acids are related with hypofibrinolysis in type 2 diabetes mellitus. Fibrinolysis. 8:1994;25-27.
4. Brussaard H.E., Gevers Leuven J.A., Krans H.M.J., Kluft C. The effect of 17β-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus. Vasc. Pharmacol. 39:2002;141-147.
5. Caine Y.G., Bauer K.A., Barzegar S., Ten Cate H., Sacks F.M., Walsh B.W., Schiff I., Rosenberg D. Coagulation activation following oestrogen administration to postmenopausal women. Thromb. Haemost. 68:1992;392-395.
6. Clauss A. Gerinnungsphysiologische Schnell methode zur Bestimmung des Fibrinogens. Acta Haematol. 17:1957;237-246.
7. Davi G., Violi F., Catalano I., Giammarresi C., Putignano E., Nicolosi G., Barbagallo M., Notarbartolo A. Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina. Blood Coagul. Fibrinolysis. 2:1991;41-45.
8. Donders S.J., Lustermans F.A.T., Van Wersch J.W.J. Glycometabolic control, lipids, and coagulation parameters in patients with non-insulin-dependent diabetes mellitus. Int. J. Clin. Lab. Res. 23:1993;155-159.
9. Donders S.J., Lustermans F.A.T., Van Wersch J.W.J. The effect of microalbuminuria on glycaemic control, serum lipids and haemostasis parameters in non-insulin-dependent diabetes mellitus. Ann. Clin. Biochem. 30:1993;439-444.
10. Ford I., Singh T.P., Kitchen S., Makris M., Ward J.D., Preston F.E. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabetes Med. 8:1991;322-329.
11. Ganda O.P., Arkin C.F. Hyperfibrinogenemia, an important risk factor for vascular complications in diabetes. Diabetes Care. 15:1992;1245-1250.
12. Gevers Leuven J.A., van der Mooren M.J., Buytenhek R. The effect of medrogestone on lipids and lipoproteins in postmenopausal women using conjugated estrogens, an open randomized comparative study. Fertil. Steril. 64:1995;525-531.
13. Gray R.P., Patterson D.L.H., Yudkin J.S. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler. Thromb. 13:1993;415-420.
14. Gray R.P., Yudkin J.S., Patterson D.L. Plasminogen activator inhibitor a risk factor for myocardial infarction in diabetic patients. Br. Heart J. 69:1993;228-232.
15. Haverkate F., Thompson S.G., Van de Loo J.C. The relationship between haemostatic tests and cardiovascular risk factors in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities (ECAT) Angina Pectoris group. Ann. Epidemiol. 2:1992;521-524.
16. Henderson B.E., Pagannini-Hill A., Ross R.K. Decreased mortality in users of oestrogen replacement therapy. Arch. Intern. Med. 1(51):1991;75-78.
17. Ingerslev I. A sensitive ELISA for van Willebrand factor VWF:ag. Scand. J. Clin. Lab. lnvest. 47:1987;143-149.
18. Jones R.L. Fibrinopeptide-A in diabetes mellitus, relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes. 34:1985;836-843.
19. Juhan-Vague I., Vague P. Interrelations between carbohydrates lipids and the haemostatic system in relation to the risk of the thrombotic and cardiovascular disease. Am. J. Obstet. Gynaecol. 163:1990;313-315.
20. Juhan-Vague I., Vague P. Hypofibrinolysis and insulin resistance. Diabetes Metab. 17:1991;96-100.
21. Kannel W.B., D'Agustino R.B., Belanger A.J. Update on fibrinogen as a cardiovascular risk factor. Ann. Epidemiol. 2:1992;457-466.
22. Kario K., Matsuo T. Lipid-related haemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis. Atherosclerosis. 103:1993;131-138.
23. Kawamori R., lmano E., Watarai T., Nishizawa H., Matsushima H., Kodama M., Yamasaki Y., Kamada T. Platelet activation in diabetic patents with asymptomatic atherosclerosis. Diabetes Res. Clin. Pract. 24:1994;89-95.
24. Kluft C. Oral contraceptives and hemostasis. Gynecol. Endocrinol. 10(Suppl. 2):1996;29-37.
25. Koopman J., Haverkate F., Koppert P., Nieuwenhuizen W., Brommer E.J.P. New enzyme immuno assay of fibrin-fibrinogen degradation products in plasma using monoclonal antibodies. J. Lab. Clin. Med. 109:1987;75-84.
26. Kroon U.B., Silfverstolpe G., Tengborn L. The effects of transdermal oestradiol and oral conjugated oestrogens on haemostasis variables. Thromb. Haemost. 71:1994;420-423.
27. Lee A.J., Lowe G.D.O., Smith W.C.S., Tunstall-Pedou H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br. J. Haematol. 8(3):1993;616-621.
28. Lindberg U.B., Crona N., Stigendal L., Teger-Nilsson A.C., Silverstolpe G. A comparison between effects of oestradiol valerate and low dose ethinyloestradiol on haemostasis parameters. Thromb. Haemost. 61:1989;65-69.
29. Marckmann P., Sandstrom B., Jespersen J. The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. Atherosclerosis. 96:1992;235-244.
30. Mayne E.E. Haemostatic disorders in diabetes mellitus. (Chapter 11) Diabetes and Atherosclerosis. Developments in Cardiovascular Medicine. 125:1992;219-235 Kluwer Academic Publishers, Dordrecht.
31. McGill J.B., Schneider D.J., Arfken C.L., Lucore C.L., Sobel B.E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 43:1994;104-109.
32. Meilahn E.N., Kuiler L.H., Matthews K.A., Kiss J.E. Haemostatic factors according to menopausal status and use of hormone replacement therapy. Ann. Epidemiol. 2:1992;445-455.
33. Mitropoulos K.A. Hypercoagulability and Factor VII in hypertriglyceridaemia. Semin. Thromb. Hemost. 14:1988;246-252.
34. Mussoni L., Mannucci L., Sirtori M., Camera M., Maderna P., Sironi L., Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler. Thromb. 12:1992;19-27.
35. Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss G., Wu K.K., Szklo M. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N. Engl. J. Med. 328:1993;1069-1075.
36. Nieuwenhuizen W., Laterveer R., Hoegee B. An enzyme immunoassay for the simultaneous determination of active type-1 plasminogen activator inhibitor (PAI-1), and t-PA/PAI-1 complexes. Blood Coagul. Fibrinolysis. 6:1995;520-526.
37. Nieuwenhuizen W., Laterveer R., Hoegee-de Nobel E., Bos R. A one-step enzyme immunoassay for total plasminogen activator inhibitor-1 antigen in human plasma. Blood Coagul. Fibrinolysis. 6:1995;268-272.
38. Nossel H.L. Relative proteolysis of the fibrinogen Bβ-chain by thrombin and plasmin as a determinant of thrombosis. Nature. 291:1981;165-167.
39. Oswaldsson U. A simple chromogenic assay for the determination of FVII in microplates. Thromb. Haemost. Abstr. 153:1985;26.
40. Pearson J.D. The control of production and release of haemostatic factors in the endothelial cell. Baillière's Clin. Haematol. 6:1993;629-651.
41. Pelzer H., Schwarz A., Heimburger N. Determinations of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb. Haemost. 59:1988;101-106.
42. Pelzer H., Pilgrim A., Schwarz A., Merte D., Keuper H., Hock H. Determination of alpha (2)-antiplasmin-plasmin complex in human plasma with an enzyme linked immunosorbent assay. Fibrinolysis. 7:1993;69-74.
43. The writing group for the PEPI trial. Effects of oestrogen or oestrogen/progestin regimens on heart disease risk factors in post-menopausal women. JAMA, J. Am. Med. Assoc. 273:1995;199-208.
44. Petersen L.C., Valentin S., Hedner U. Regulation of the extrinsic pathway system in health and disease: the role of FVIla and tissue factor pathway inhibitor. Thromb. Res. 79:1995;1-47.
45. Ranby M., Bergsdorf N., Nilsson T., Mellbring G., Winblad B., Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent. Clin. Chem. 32:1986;2160-2165.
46. Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., Hennekens C.H. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet. 341:1993;1165-1168.
47. Ridker P.M., Hennekens C.H., Stampfer M.J., Manson J.E., Vaughan D.E. Prospective study of endogenous tissue type plasminogen activator and risk of stroke. Lancet. 343:1994;940-943.
48. Saleh A.A., Dorey L.G., Dombrowski M.P., Ginsgurg K.A., Hirokawa S., Kowalczyk C., Hirata J., Bottoms S., Cotton D.B., Mammen E.F. Thrombosis and hormone replacement therapy in postmenopausal women. Am. J. Obstet. Gynecol. 169:1993;1554-1557.
49. Schneider D.J., Nordt T.K., Sobel B.E. Perspectives in diabetes: attenuated fibrinolysis and accelerated atherogenesis in type 2 diabetic patients. Diabetes. 42:1993;1-7.
50. Stampfer M.J., Willett W.C., Colditz G.A., Rosner B., Speizer F.E., Hennekens C.H. A prospective study of postmenopausal oestrogen therapy and coronary heart disease. N. Engl. J. Med. 313:1985;1044-1049.
51. Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Rosner B., Speizer F.E., Hennekens C.H. Postmenopausal oestrogen therapy and cardiovascular disease. Ten year follow-up from the Nurses Health Study. N. Engl. J. Med. 325:1991;756-762.
52. Stehouwer C.D.A., Nauta J.J.P., Zeldenrust G.C., Hackeng W.H.L., Donker A.J.M., Den Ottolander G.J.H. Urinary albumin excretion, cardiovascular disease and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 340:1992;319-323.
53. Stiko-Rahm A., Wiman B., Hamsten A., Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 10:1990;1067-1073.
54. Wersch van J.W.J., Donders S.H.J., Westerhuis L.W.J.J.M., Venekamp W.J.R.R. Microalbuminuria in diabetic patients: relationship to lipid, glyco-metabolic, coagulation and fibrinolysis parameters. Eur. J. Clin. Chem. Clin. Biochem. 29:1991;493-498.
55. Wiman B., Ranby M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb. Haemost. 55:1986;189-193.
56. Winkler U.H. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis. 6:1992;5-10.
57. Winkler U.H., Koslowski S., Oberhoff C., Schindler E.M., Schindler A.E. Changes of the dynamic equilibrium of hemostasis associated with the use of low-dose oral contraceptives: a controlled study of cyproterone acetate containing oral contraceptives combined with either 35 or 50 μg ethinyl estradiol. Adv. Contracep. 7(Suppl. 3):1991;273-284.